THE APEX TIMES
The agreement covers three in vivo CAR-T therapies still at the pre-IND stage, with Pfizer gaining rights outside China as part of a large upfront and development-linked structure reported by trade media.
Pfizer has signed a $2.6 billion deal with China’s Starna to secure ex-China rights to three autoimmune in vivo CAR-T programmes, according to a report published by pharmaceutical-industry trade outlet Pharmaceutical Technology on Nov. 19, 2026.
CAR-T therapies are a class of treatments that use a patient’s immune cells, engineered to recognize and attack disease. In vivo CAR-T refers to approaches designed to create or activate these engineered cells inside the patient rather than outside the body, which can change both manufacturing requirements and how treatments are delivered.
Under the reported terms, the programmes Pfizer is acquiring are at the pre-IND stage. “Pre-IND” generally means the therapies are not yet in the formal Investigational New Drug application process with regulators, which typically comes after earlier preclinical work and preparation of trial-enabling documentation.
The report frames the agreement as part of Pfizer’s broader strategy to build out its cell therapy pipeline by adding assets that are not yet in clinical testing. It also suggests the deal is structured to compensate Starna for the value of early-stage science and expected future development work, though the publication does not provide additional specifics in the information available here.
For Pfizer, outsourcing or licensing stage progress is one way to diversify a pipeline while managing the risk inherent in early oncology and immunology technologies. For Starna, a large upstream deal can provide development funding and reduce the need to finance clinical pathways entirely from internal resources, particularly for platforms that require technical know-how and sustained investment before trials can begin.
Cell therapies have drawn intense interest from large drugmakers because they can be curative in certain settings, but they also come with execution challenges, including regulatory hurdles, manufacturing scale-up, and long lead times. In vivo CAR-T programmes, in particular, are still in the proof-and-optimization phase for many indications, which makes pre-IND timing a critical juncture for both partners.
The reported announcement does not disclose, in the information provided here, which specific autoimmune diseases the three CAR-T programmes are targeting, the allocation of responsibilities between the two companies for clinical development and regulatory submissions, or the expected timing for moving each programme into IND filing and first-in-human studies.
Investors and industry observers will likely watch for later disclosures on target indications, trial designs, the payment structure (for example, how much is upfront versus milestone-based), and which company will lead regulatory interactions for the territories outside China.
A new market discussion highlights Lilly’s push to expand its immunology franchise, pointing to rising product demand, a developing pipeline, and potential deal activity. The company has not detailed all immunology-specific milestones in the public discussion, leaving some questions open.
A Yahoo Finance-linked post said UnitedHealth Group Inc. is among the most watched stocks on Zacks.com, prompting renewed focus on the company factors investors typically track next.
The company announced the Houston hospital will become the first commercial site for the OTTAVA robotic platform, marking a new step in J&J’s push to expand in surgical robotics.
The biotechnology company said it expects 2027 cash costs around $4 billion, with annual costs potentially reaching up to about $4.5 billion through 2030, drawing a sharp market reaction.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...